Contrast Enhanced Spectral Mammography for the Evaluation of Pathologic Nipple Discharge

• Status: Recruiting
• Trial end date: 2023-03-01
• Target enrollment: 0
• Participant gender: Female

Summary

This clinical trial studies contrast enhanced spectral mammography (CESM) for the evaluation of pathologic nipple discharge. CESM is similar to standard mammography, but it includes an intravenous (by vein) injection of an iodine-based contrast, which makes tissue and blood vessels more visible in scans. The goal of this trial is to learn if CESM, is better than standard mammography in quickly and efficiently determining the cause of nipple discharge and detecting breast cancer, if present. CESM may increase the chance of finding breast cancers and lower the risk of having unnecessary biopsies.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: M.D. Anderson Cancer Center

Criteria

Inclusion Criteria:

• Women presenting to M D Anderson Cancer Center (MDACC) for the evaluation of PND as the main or accompanying symptom

• Age 25-85 years

• Willing to participate in the study and undergo an IV placement, able to undergo iodinated contrast injection, and able to provide informed consent

Exclusion Criteria:

• Reported history of an allergic reaction to iodinated contrast

• History of anaphylactic reaction to any substance

• Renal insufficiency

• Pregnancy or lactation within 6 months

• Breast surgery affecting the symptomatic breast within prior 6 months, if it was located within 5 cm from the nipple

• Breast biopsy of the symptomatic breast within the last 2 months, if it was located within 5 cm from the nipple